Crescita Therapeutics Inc. (CRRTF)
OTCMKTS · Delayed Price · Currency is USD
0.3663
+0.0352 (10.63%)
At close: Jan 22, 2026
Crescita Therapeutics Revenue
Crescita Therapeutics had revenue of 5.39M CAD in the quarter ending September 30, 2025, with 50.06% growth. This brings the company's revenue in the last twelve months to 22.07M, up 26.79% year-over-year. In the year 2024, Crescita Therapeutics had annual revenue of 19.58M with 11.75% growth.
Revenue (ttm)
22.07M CAD
Revenue Growth
+26.79%
P/S Ratio
0.42
Revenue / Employee
n/a
Employees
n/a
Market Cap
6.64M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 19.58M | 2.06M | 11.75% |
| Dec 31, 2023 | 17.52M | -6.00M | -25.52% |
| Dec 31, 2022 | 23.53M | 6.76M | 40.29% |
| Dec 31, 2021 | 16.77M | 1.13M | 7.22% |
| Dec 31, 2020 | 15.64M | -6.70M | -29.98% |
| Dec 31, 2019 | 22.34M | 5.71M | 34.33% |
| Dec 31, 2018 | 16.63M | 4.61M | 38.41% |
| Dec 31, 2017 | 12.01M | 8.51M | 242.87% |
| Dec 31, 2016 | 3.50M | 3.28M | 1,436.84% |
| Dec 31, 2015 | 228.00K | -602.00K | -72.53% |
| Dec 31, 2014 | 830.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CV Sciences | 14.37M |
| CordovaCann | 10.20M |
| Tristar Wellness Solutions | 4.00M |
| Cannabis Bioscience International Holdings | 148.34K |
| Rafarma Pharmaceuticals | 133.33K |
| Full Alliance Group | 82.12K |
Crescita Therapeutics News
- 3 months ago - Crescita Therapeutics Swings To Profit In Q3 - Nasdaq
- 3 months ago - Crescita Reports Third Quarter 2025 Results - Business Wire
- 6 months ago - Crescita Reports Second Quarter 2025 Results - Business Wire
- 9 months ago - Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders - Financial Post
- 9 months ago - Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders - Business Wire
- 9 months ago - Crescita Therapeutics Announces Mutual Termination of Licensing Agreement with Croma Pharma GmbH for Pliaglis® - Financial Post
- 9 months ago - Crescita Therapeutics Announces Mutual Termination of Licensing Agreement with Croma Pharma GmbH for Pliaglis® - Business Wire
- 9 months ago - Crescita Reports First Quarter 2025 Results - Business Wire